by Lyla El-Fayomi | May 23, 2024
“Regenerative medicine news under the microscope” is a monthly feature highlighting a selection of impactful research findings and headlines across the many subfields of regenerative medicine. I’ve gone slightly longer form with this month’s edition, as I found that...
by Stacey Johnson | Feb 23, 2024
As a fair-skinned, freckled person (my mom says she painted them on me while I slept), and one who has a family history of skin cancers and melanoma, the news on February 19 that Iovance Biotherapeutics’ AMTAGVITM received U.S. Food and Drug Administration (FDA)...
by Stacey Johnson | Dec 29, 2023
It’s been a busy year in the cell and gene therapy community and the bloggers at Signals have enjoyed putting the spotlight on news (HeLa settlement and UK rejoins Horizon Europe), scientific advances (improving treatment for hematological malignancies and a new...
by Peace Chukwu | Dec 14, 2023
When Caitlin Brodnick tested positive for the BRCA1 gene mutation, she decided to have a preventative double mastectomy. But she was afraid of losing her breasts and worried about the reconstruction, and top on the list was how real they were going to look....
by Stacey Johnson | Dec 1, 2023
Do you remember the column “Life, Interrupted” by cancer patient Suleika Jaouad? She was 22 when she was diagnosed with acute myeloid leukemia (AML) and a rare blood disorder called myelodysplastic syndrome. With her hopes to be a war correspondent on hold (dashed?),...
by Kevin Robb | Nov 9, 2023
BlueRock Therapeutics has generated considerable media buzz with their announcement of positive Phase I clinical trial data on bemdaneprocel (BRT-DA01), an investigational, stem cell-derived, dopaminergic therapy for Parkinson’s disease. The trial is the result of...
Comments